The vector manufacturing market is anticipated to be worth USD 1.65 billion by 2030, growing at an annualized rate of over 20%, claims Roots Analysis

Given the rise in clinical R&D activity focused on gene therapies and other advanced therapy medicinal products, there has been a surge in demand for various types of vectors, resulting in significant opportunities for contract service providers

Roots Analysis has announced the addition of Viral Vector and Plasmid DNA Manufacturing Market report to its list of offerings. 

Complex production protocols, coupled to high product development costs and affiliated expenses, have compelled many innovator companies to outsource vector manufacturing operations to capable CMOs / CDMOs. Such contract service providers are known to possess significant expertise and dedicated GMP facilities to produce safe and high-quality products.

To order this 445+ page report, which features 100+ figures and 125+ tables, please visit https://www.rootsanalysis.com/reports/viral-vectors-non-viral-vectors-and-gene-therapy-manufacturing-market-/274.html

Key Market Insights 

Over 160 companies / organizations currently claim to provide viral vector and plasmid DNA manufacturing services

More than 50% of the industry players engaged in this domain are large or mid-sized firms (with more than 50 employees). Further, the growing demand for these products has spurred the establishment of many start-ups. In addition, more than 60 non-industry players are involved in this field. 

The US and EU are presently considered as major vector manufacturing hubs

Approximately 52% of the vector manufacturing facilities are located in North America. Further, close to 38% of the world’s vector manufacturing facilities are based in the EU. This trend can be attributed to the high volume of active clinical studies, which require vectors, being conducted in the aforementioned regions.

Players are actively trying to expand their operations to meet the anticipated demand 

Approximately 80% of industry stakeholders claim to manufacture vectors at the laboratory and / or clinical scales. However, some firms (around 30) have also developed / are developing commercial scale capabilities for vector production. 

The current installed vector manufacturing capacity is estimated to be over 50,000 L

It is worth noting that companies manufacturing vectors at both clinical and commercial scales capture a major share (70%) of the global vector manufacturing capacity. Further, owing to the presence of a large number of small-sized and mid-sized companies, 50% of the total capacity is presently available in the US.

Several partnerships have been inked by industry stakeholders to support ongoing therapy development efforts

Around 80 agreements were inked during the last three years; interestingly, the maximum number of instances (31) were reported in 2016, followed by 22 partnerships in 2017. In addition, around 30% of the deals were related to the manufacturing of vectors across different scales of operation; this was followed by technology licensing agreements (26%).

Around 90% of the market share is captured by viral vectors intended for use in oncological disorders 

Presently, manufacturing operations involving lentiviral vectors represent the largest share (in terms of anticipated revenues generated) of the market, followed by retroviral vectors. This can be attributed to the fact that several T-cell based therapies, requiring the aforementioned vector types, are being evaluated in clinical studies. 

You Can Download Free Sample PDF Copy of This Report At:
https://www.rootsanalysis.com/reports/viral-vectors-non-viral-vectors-and-gene-therapy-manufacturing-market-/request-sample.html

Key Questions Answered

• How is the current and future market opportunity (related to vector manufacturing) likely to be distributed across key market segments?
• What is the installed vector manufacturing capacity and how it is distributed across key geographical regions?
• Who are the leading industry and non-industry players engaged in this market?
• What are the various types of vectors used in the production of cell and gene therapies?
• What are the recent developments and enabling technologies that are likely to influence the future of vector manufacturing?

The USD 1.65 billion (by 2030) financial opportunity within the vector manufacturing market has been analyzed across the following segments:

• Type of Vector
  • AAV
  • Adenoviral
  • Lentiviral
  • Retroviral
  • Plasmid DNA
  • Other Viral Vectors
• Application
  • Gene Therapy
  • T-Cell Therapy
• Therapeutic Area
  • Oncology
  • Inflammation & Immunology
  • Ophthalmology
  • Metabolic Disorders
  • Cardiovascular Disorders
  • Others 
• Scale of Operation
  • Clinical
  • Commercial
• Key geographical regions 
  • North America
  • Europe
  • Asia Pacific
  • Rest of the World

The report features inputs from eminent industry stakeholders, according to whom several new companies, including various university spin-offs, have recently entered the vector manufacturing business and are likely to experience rapid growth owing to the growing demand. The report includes detailed transcripts of discussions held with the following experts:

• Joost van den Berg (Director, Amsterdam BioTherapeutics Unit)
• Semyon Rubinchik (Scientific Director, ACGT)
• Nicole Faust (Chief Executive Officer & Chief Scientific Officer, CEVEC Pharmaceuticals)
• Olivier Boisteau, (President / Co-Founder), Laurent Ciavatti (Business Development Manager) and Xavier Leclerc (Head of Gene Therapy, Clean Cells)
• Colin Lee Novick (Managing Director, CJ Partners)
• Cedric Szpirer (Executive & Scientific Director, Delphi Genetics)
• Nicolas Grandchamp (R&D Leader, GEG Tech)
• Bakhos A Tannous (Director, MGH Viral Vector Development Facility, Massachusetts General Hospital)
• Alain Lamproye (President of Biopharma Business Unit, Novasep)
• Astrid Brammer (Senior Manager Business Development, Richter-Helm)
• Marco Schmeer (Project Manager) and Tatjana Buchholz (Marketing Manager, Plasmid Factory)
• Jeffrey Hung (Chief Commercial Officer, General Manager of cGMP Business, Vigene Biosciences)
• Brain M Dattilo (Business Development Manager, Waisman Biomanufacturing)

The research includes brief profiles of several companies (listed below), featuring an overview of the company, financial information (if available), vector manufacturing technology, manufacturing facilities, vector manufacturing experience and an informed future outlook.

• Aldevron
• BioReliance (a part of SAFC Commercial)
• Biovian
• bluebird bio
• Brammer Bio
• Cell and Gene Therapy Catapult
• Cobra Biologics
• FinVector
• FUJIFILM Diosynth Biotechnologies
• Kaneka Eurogentec
• Lonza
• MassBiologics
• MolMed
• Novasep
• Oxford BioMedica
• Richter-Helm
• Sanofi (CEPiA, Sanofi Pasteur, Genzyme)
• Spark Therapeutics
• uniQure
• Vigene Biosciences
• VIVEbiotech
• WuXi AppTec

For additional details, please email at sales@rootsanalysis.com 

Contact:

Gaurav Chaudhary
Gaurav.Chaudhary@rootsanalysis.com